CONICET Researcher Analyzes Ethics of Genetic Screening for Donors
Genetic carrier screening for egg and sperm donors aims to identify recessive gene variants that could lead to inherited conditions in offspring. While these tests offer prospective parents and clinics more data, they remain non-mandatory in Argentina, and experts warn that such panels must be balanced against potential ethical risks and the need for clear counseling.
Key Clinical Takeaways:
- Carrier screening identifies gene variants that may cause disease if both donors carry the same mutation, though it provides risk estimates rather than absolute certainty.
- The Sociedad Argentina de Medicina Reprodutiva (SAMER) currently mandates karyotyping—an analysis of chromosome structure and count—rather than universal genetic carrier screening for donors.
- Bioethicists emphasize that informed consent is complex, requiring that donors fully grasp the implications of revealing health data about themselves and their biological relatives.
Genetic testing protocols for reproductive donors
Genetic carrier screening evaluates specific DNA sequences to determine if an individual carries mutations that, when paired with a corresponding variant from a co-parent, could result in a clinical condition. In the context of assisted reproduction, these tests are increasingly applied to gamete donors to reduce the transmission of hereditary disorders.
Natacha Salomé Lima, a bioethics researcher at CONICET, analyzed current practices in a study that earned recognition at the 2026 Premio Anual de Bioética, hosted by the Fundación Dr, according to Diario Río Negro | Periodismo en la Patagonia. Jaime Roca. Her research examined documentation from a fertility clinic, a gamete bank, and three genetic testing firms to assess how this information is handled.
Broad genetic panels create information imbalance for donors
Broad genetic panels create a major information imbalance. While recipients and potential children may gain health insights, donors often undergo testing without fully anticipating the impact of the results on their own medical profiles or those of their families.
“Existe una asimetría: los receptores y los hijos pueden beneficiarse, mientras que los donantes necesitan comprender los resultados,” said Natacha Salomé Lima, bioethics researcher at CONICET, during her investigation of informed consent practices.
Lima also warned that high-throughput genetic panels—which scan for a large number of conditions simultaneously—carry the risk of reinforcing social prejudices. She said that presenting certain human traits or variations as conditions to be avoided can stigmatize biodiversity.
Regulatory gaps in Argentine clinical practice
In Argentina, the clinical standard for donors does not currently include mandatory genetic carrier screening. According to the consensus guidelines issued by the Sociedad Argentina de Medicina Reprodutiva (SAMER), the recommended protocol is the karyotype. This test allows clinicians to observe the number and structure of chromosomes, providing a broad overview of the donor’s genetic health.
The study by Lima highlighted a critical limitation in expanding these tests: the absence of a comprehensive national reference genome. Without a standardized sequence representative of the local population, interpreting specific variants and deciding which conditions to include in screening panels remains a challenge. Accurate risk assessment requires reliable data on the frequency of genetic diseases within the specific population, which is currently insufficient in the country.
The necessity of clinical genetic counseling
Medical professionals emphasize that the utility of genetic testing is fundamentally tied to the quality of counseling provided before and after the procedure. Signing a consent form does not inherently ensure that a donor understands the complex biological or familial consequences of the test results. “Los donantes necesitan conocer alcances, límites y consecuencias,” Lima said in her research. She underscored that while genetic analysis provides substantial data, it does not offer absolute certainty regarding the future health of offspring, nor can it eliminate all reproductive risks.
Patients or individuals considering the use of donor gametes should seek guidance from qualified reproductive endocrinologists or clinical geneticists to navigate these testing options. These specialists can help interpret the clinical relevance of carrier status and explain the limitations of current diagnostic panels.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.